For U.S. patients with idiopathic pulmonary fibrosis (IPF), nerandomilast slows the decline in forced vital capacity (FVC), ...

For U.S. patients with idiopathic pulmonary fibrosis (IPF), nerandomilast slows the decline in forced vital capacity (FVC), ...

In idiopathic pulmonary fibrosis, the lung tissue thickens and stiffens through proliferation of fibroblasts and invasion by inflammatory cells. One of the drivers of these processes is the enzyme ...

Brainomix said its e-Lung software detects lung scarring and may help with earlier diagnosis and more accurate monitoring of ...

Credit: Getty Images The road to race-neutral pulmonary function testing has been long and evolving; now, ATS recommends this approach and a Boston hospital offers an implementation model. In July, ...

Findings showed nerandomilast led to a slower decline in absolute change from baseline in FVC compared with placebo. The Food and Drug Administration (FDA) has approved Jascayd ® (nerandomilast) for ...

EMA approval covers study sites in Germany and Poland as part of the Company’s global Phase 2 RENEW trial Trial will evaluate LTI-03, a first-in-class therapy designed to both reduce lung scarring and ...

It might start with a shortness of breath that’s easily dismissed as getting older or needing more exercise. But for the nearly 3 million patients with idiopathic pulmonary fibrosis (IPF), this subtle ...

CLEVELAND — The number of people diagnosed with idiopathic pulmonary fibrosis is expected to grow substantially over the next decade, according to new forecasts from a global health data analytics ...

Abstract: Summary–Pneumonia, an acute respiratory infection marked by inflammatory responses typically manifesting in the alveoli, distal airways, and pulmonary interstitium, poses a substantial risk ...